Basic Addyi Information

• INN (International Nonproprietary Name): Flibanserin.
• Brand Names Available In Canada (English): Addyi — marketed in Canada as 100 mg oral tablets by Sprout Pharmaceuticals; also listed as flibanserin or flibanserin‑hydrochloride in some listings.
• ATC Code: G02CX02 (Other Gynecologicals, Miscellaneous).
• Forms & Dosages: Tablet, oral, 100 mg, Sprout Pharmaceuticals; blister packs (usually 30 tablets per carton).
• Manufacturers In Canada (English): Supplied by Sprout Pharmaceuticals, Inc. (United States) as the sole approved supplier in primary markets.
• Registration Status In Canada (English): Approved by Health Canada for acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women; prescription only.
• OTC / Rx Classification: Prescription only (Rx) in all jurisdictions where approved.

Key Findings From Recent Trials

Clinicians want to know whether recent research changes how addyi is used in Canada.

Recent publications from 2022–2025 focused on real‑world evidence, pooled re‑analyses, and observational cohorts rather than new large randomized trials.

Canadian cohort and clinic‑level observational reports reviewed flibanserin prescriptions in premenopausal women and aligned with international post‑marketing surveillance findings.

Most reports described modest improvements in patient‑reported sexual desire scores compared with baseline.

Placebo‑adjusted benefit varied across studies because outcome measures were heterogeneous.

Regulatory safety reviews during this interval highlighted increased hypotension and syncope risk when flibanserin was combined with alcohol or CYP3A4 inhibitors.

Rare hypersensitivity reports emerged and were under review by regulators in 2024–2025.

Health Canada reaffirmed the approved indication for HSDD in premenopausal women and recommended the 100 mg bedtime dosing with assessment at eight weeks.

Market context remained stable: no authorized generics as of mid‑2025 and Sprout remained the sole supplier, with patents extending to May 9, 2028.

Key data gaps persist, including heterogeneous outcome measures across studies and limited long‑term comparative effectiveness data.

Province‑level coverage analyses in Canada remained sparse, so access and funding data are incomplete for prescribers and pharmacists.

For Canadian clinicians, the strongest recent evidence comes from pragmatic real‑world cohorts and pooled safety reports rather than fresh phase III trials.

Main Outcomes

Patient‑reported desire scores typically showed modest increases from baseline in clinic cohorts and post‑marketing analyses.

Placebo‑controlled re‑analyses reported variable effect sizes depending on the instrument used.

Clinical guidance therefore emphasises shared decision‑making and setting realistic expectations about modest typical benefit.

Safety Observations

Post‑marketing surveillance flagged hypotension and syncope particularly when flibanserin was combined with alcohol or moderate/strong CYP3A4 inhibitors.

Rare hypersensitivity reports were under regulatory review during 2022–2025.

Bedtime dosing remains recommended to reduce daytime somnolence and dizziness.

Clinical Mechanism Of Action

Patients often ask, "How does addyi actually work?"

Flibanserin is a daily oral medication intended to increase sexual desire in premenopausal women by rebalancing brain chemicals involved in sexual motivation rather than acting on genital blood flow.

It is not an on‑demand sexual stimulant; steady dosing is required and effects are assessed at eight weeks.

Scientific Breakdown

Flibanserin is a centrally acting agent with affinity for serotonergic and dopaminergic receptors.

Its primary pharmacology is 5‑HT1A agonism and 5‑HT2A antagonism, which leads to downstream increases in dopamine and norepinephrine signalling in brain regions associated with sexual desire.

That neuromodulation contrasts with PDE5 inhibitors that act peripherally on vasodilation.

The marketed dose is 100 mg oral tablets taken at bedtime to reduce somnolence and dizziness.

Flibanserin is contraindicated with moderate or strong CYP3A4 inhibitors and in severe hepatic impairment because exposure increases and hypotension/syncope risk rises.

Scope Of Approved And Off‑Label Use

Clinicians commonly ask whether addyi is approved for other groups beyond premenopausal women.

Health Canada approved addyi for acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, packaged as flibanserin 100 mg tablets from Sprout Pharmaceuticals.

Use follows the product monograph: 100 mg nightly at bedtime with efficacy assessment at eight weeks.

In Canada, prescriptions should be dispensed using the correct Drug Identification Number (DIN) and bilingual labelling at the pharmacy.

Notable Off‑Label Trends In Canadian Practice

Some Canadian prescribers consider off‑label interventions for low desire such as testosterone formulations, compounded therapies, and psychosexual therapy referral.

Off‑label prescribing of addyi to postmenopausal women or men is not supported by Health Canada and lacks robust evidence.

Documented practice patterns typically reserve pharmacologic therapy for patients who have completed psychosocial assessment and treatment of reversible causes.

Safety constraints—especially the alcohol interaction and CYP3A4 contraindications—mean off‑label use requires caution and thorough documentation.

Dosage Strategy

One common question is, "What is the right dose and when should benefits be checked?"

The standard regimen per Health Canada and the product monograph is 100 mg orally once daily at bedtime.

Bedtime administration reduces daytime somnolence and dizziness and matches regulatory recommendations.

Efficacy should be assessed after eight weeks and the medication discontinued if no meaningful benefit is observed.

Condition‑Specific Dosing Adjustments

Flibanserin is contraindicated in severe hepatic impairment because exposure and adverse effects increase.

Co‑administration with moderate or strong CYP3A4 inhibitors is also contraindicated due to elevated hypotension and syncope risk.

There are insufficient data to recommend routine use in renal impairment, older/postmenopausal women, or children.

If a patient misses a dose, they should skip it and take the next dose at the regular time; doubling is not advised.

Pharmacists should counsel on interactions with psychotropics and CNS depressants and recommend prescriber review if needed.

Safety Protocols

Safety is usually the first concern patients raise when addyi is discussed.

Absolute contraindications include severe hepatic impairment and concomitant use with moderate or strong CYP3A4 inhibitors.

Known hypersensitivity to flibanserin or excipients is also an absolute contraindication.

Adverse Effects And Monitoring

Common adverse effects reported in trials and post‑marketing surveillance include dizziness, somnolence, nausea, insomnia, and dry mouth.

Post‑marketing surveillance from 2022–2025 emphasised hypotension and syncope risk when combined with alcohol or interacting drugs.

Rare hypersensitivity events have been reported and are under regulatory review.

Pharmacists should counsel patients to avoid alcohol around dosing and to take the tablet at bedtime to reduce daytime sedation.

In overdose, management is supportive and clinicians should watch for severe hypotension, excessive sedation, and syncope.

Documenting informed consent and counselling in clinic notes is advised because benefits are modest and safety concerns are established.

Interaction Mapping

Patients often ask whether they can take addyi with other medicines or with a glass of wine.

The major interaction class is CYP3A4 inhibitors — moderate and strong inhibitors increase flibanserin levels and the risk of hypotension and syncope.

Examples of interacting drugs include certain antifungals, macrolide antibiotics, and some antiretrovirals; pharmacists should check interaction tools at dispensing.

Concomitant CNS depressants such as benzodiazepines and opioids may increase somnolence and dizziness when combined with flibanserin.

SSRIs and SNRIs should be assessed for interaction risk though routine co‑prescribing is common with monitoring.

Food And Alcohol Considerations

Alcohol co‑administration is strongly discouraged and is contraindicated in US labelling because it can precipitate severe hypotension and syncope with flibanserin.

Canadian advisories echo strong caution and recommend avoiding alcohol around dosing times.

Bedtime dosing helps separate the dose from evening alcohol consumption for many patients.

High‑fat meals do not require dose adjustment but may affect tolerability in some patients.

Patient Experience Analysis

Many patients want to hear real experiences from other Canadians before trying addyi.

Canadian surveys and clinic feedback from 2022–2025 show mixed satisfaction with flibanserin for HSDD in premenopausal women.

Some patients report meaningful improvements in desire and relationship satisfaction, while others report minimal benefit and discontinue by eight weeks.

Common patient complaints include daytime drowsiness, nausea, and the alcohol restriction, which some find a barrier to adherence.

Community pharmacists at national chains report low but steady dispensing volumes and prioritise counselling on bedtime dosing and interaction screening.

Online forums and patient groups show polarized views, with positive anecdotes balanced by reports of side effects and cost concerns.

Clinicians should set expectations, use shared decision‑making, and schedule an eight‑week follow‑up to assess response and tolerability.

Distribution And Pricing Landscape

Access and cost are practical concerns for many Canadian patients considering addyi.

Addyi (flibanserin 100 mg) is available by prescription through major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs, and through licensed community pharmacies.

Availability can vary by store and region and some pharmacies may need to special order product from the supplier.

Provincial public formularies like Ontario Drug Benefit, BC PharmaCare, and RAMQ do not uniformly list addyi, and coverage often requires exceptional access or private insurance.

Out‑of‑pocket cost in Canada frequently exceeds many patients’ budgets without private coverage.

Cross‑border comparisons with the US show pricing differences driven by private insurance, patient assistance programs, and market factors.

Patients should be warned about unverified online sellers marketing unauthorized generics or counterfeit product.

For safe procurement, patients should use licensed Canadian pharmacies and verify prescription authenticity.

In our online pharmacy, addyi is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Cross‑Border And Online Availability

Some patients explore US or international suppliers, but prescription requirements and importation rules apply.

Fraudulent generics sometimes appear online; these are not approved and may be unsafe.

Pharmacists should counsel patients to use verified Canadian or licensed international pharmacies and to ask about product origin at point of sale.

Alternative Options

Patients often ask, "What else can we try besides addyi?"

There are no direct oral pharmacologic equivalents to flibanserin approved for HSDD as of 2025.

Bremelanotide (Vyleesi) is an injectable option for HSDD in some jurisdictions and works by a different mechanism, but it is not an oral alternative.

Off‑label testosterone formulations and compounded products are sometimes used in Canada for select patients but lack robust Health Canada‑approved indications for HSDD.

Pros And Cons Checklist

• Addyi (Flibanserin): Pros — Health Canada approval for premenopausal HSDD and oral daily dosing.
• Cons — Modest efficacy, alcohol/interaction constraints, potential side effects, and cost/access challenges.
• Vyleesi (Bremelanotide): Pros — On‑demand injectable for some patients; Cons — Injection route, different adverse‑event profile, variable availability.
• Testosterone/Compounded Therapies: Pros — Sometimes effective for specific hypoactive cases; Cons — Limited evidence and monitoring/regulatory concerns.

Regulatory Status

Health Canada approved flibanserin for premenopausal women with acquired, generalized HSDD and classifies the product as prescription only.

The product carries a Drug Identification Number (DIN) that pharmacists must verify at dispensing and packaging must be bilingual English/French.

Regulatory history includes earlier FDA rejections before approval in 2015, and patents remain active through May 9, 2028 in primary markets.

Post‑market surveillance and reporting obligations to Health Canada continue, and recent hypersensitivity signals have been reported and reviewed.

DIN And Labelling Rules

Pharmacies should confirm the current DIN and ensure bilingual labelling is present on the carton and patient information leaflets.

Advertising and promotion must stay within the approved indication and comply with Canadian regulatory rules.

Consolidated FAQ

Q1: Is addyi available in Canada and who can take it?

A1: Yes — Addyi (flibanserin 100 mg tablets) is approved for premenopausal women with acquired, generalized HSDD.

It is not indicated for postmenopausal women, men, or children.

Q2: How long before I know if it works?

A2: Take nightly at bedtime and assess benefit after eight weeks; discontinue if no improvement.

Q3: Can I drink alcohol while taking addyi?

A3: Alcohol is strongly discouraged or contraindicated with addyi due to hypotension and syncope risk; avoid drinking around dosing times.

Q4: Will public drug plans cover it?

A4: Coverage varies by province and many patients rely on private insurance or exceptional access; check with your provincial plan or pharmacy.

Q5: What are common side effects?

A5: Typical side effects include dizziness, sleepiness, nausea, insomnia, and dry mouth; report severe hypotension or allergic reactions to Health Canada.

Visual Guide

Suggested patient infographics should include a dosage flowchart: prescription → nightly 100 mg at bedtime → 8‑week assessment → continue/stop.

Safety icons should highlight alcohol as a red flag, CYP3A4 inhibitors as a red flag, and severe hepatic impairment as a stop sign.

A provincial coverage map should prompt viewers to check Ontario Drug Benefit, BC PharmaCare, and RAMQ because coverage is variable.

Purchase channel icons should show licensed pharmacy logos and a warning symbol for unverified online sellers.

Design notes: include bilingual labels (English/French), DIN prominence, and boxed counselling bullets such as "Avoid alcohol," "Report dizziness/syncope," and "Store at 20–25°C."

Storage And Transport

Store flibanserin tablets at controlled room temperature, 20–25°C (68–77°F), in the original blister packaging and protect from moisture and excessive heat.

No refrigeration or cold‑chain transport is required for addyi.

Advise patients travelling across provinces or internationally to carry medication in original packaging with prescription documentation and to be aware of importation rules.

Dispose of unused tablets following local pharmaceutical waste guidelines.

Guidelines For Proper Use

Pharmacists should verify the indication (premenopausal HSDD) and screen for severe hepatic impairment and interacting drugs before dispensing addyi.

Counsel on bedtime dosing, strict alcohol avoidance, missed‑dose instructions (skip missed dose), and signs that require urgent care such as fainting or severe hypotension.

Document counselling and any adverse effects in the patient record and follow institutional policies for high‑risk medications.

Provincial health authorities may have specific guidance on coverage and exceptional access pathways, so check Ontario Drug Benefit, BC PharmaCare, and RAMQ when advising patients.

Use shared decision‑making to explain the modest typical benefit, possible side effects, lifestyle constraints, and alternative treatments like psychotherapy or on‑demand injectable options.

Delivery Across Canada (English)

Final Notes For Clinicians And Pharmacists

When counselling patients about addyi, be clear about the approved population: premenopausal women with acquired, generalized HSDD.

Always screen for severe hepatic impairment and concurrent use of CYP3A4 inhibitors or alcohol use before initiating therapy.

Set expectations that typical benefit is modest and that assessment at eight weeks determines continuation.

Record informed consent and counselling in the chart, and report any suspected adverse reactions to Health Canada.

For procurement and patient safety, recommend licensed Canadian pharmacies and verify DIN and bilingual labelling at dispensing.